secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-01-14T23:59:59+00:00
Accession:  0001326110-26-000004
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Saudi FDA grants accelerated approval for ImmunityBio's ANKTIVA in NSCLC and NMIBC
--------------------------------------------------------------------------------

- SFDA approved ANKTIVA + checkpoint inhibitor for metastatic NSCLC after standard-of-care failure; first worldwide approval for this subcutaneous IL-15 agonist.
- Approval based on QUILT-3.055 and QUILT-2.023 showing lymphocyte recovery and survival association; confirmatory trial ResQ-201A recruiting.
- SFDA also approved ANKTIVA + BCG for BCG-unresponsive NMIBC with CIS, adding to U.S., U.K., and conditional EU approvals.
- ImmunityBio plans regional office in Saudi Arabia and partner Biopharma Cigalah for MENA commercial distribution; NMIBC trial enrollment ahead of schedule, BLA submission by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000004/0001326110-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000004/ibrx-20260114.htm
  HTML page:      https://secwatch.observer/filing/0001326110-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer